Company profile
Nika Pharmaceuticals Inc.
OTC: NIKA · Healthcare · Drug Manufacturers - Specialty & Generic
#1161 of 1,418 Healthcare companies by revenue
EA Score
29DFH 30DQ 23GM —SS 42
v0.1 · 55/100 weight · provisional
↑ Altman-Z, market scale · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$76.4k
Employees
—
as of 2026-08-11
Market cap
$534.8M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02024
Net income-$76.4k-$76.4k2025
Operating income-$76.4k-$76.4k2025
Total assets$21.0k$21.0k2025
Liabilities$318.6k$318.6k2025
Equity-$297.6k-$297.6k2025
Revenue trend
FY2021 – FY2024 · USD
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Nika Pharmaceuticals Inc.’s revenue?
Nika Pharmaceuticals Inc. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Neurogene Inc.43DArtiva Biotherapeutics, Inc.41DContineum Therapeutics, Inc.57CBenitec Biopharma Inc.47DLarimar Therapeutics, Inc.39DCompass Therapeutics, Inc.51DNeighbors
Clark →Key facts
CEODimitar Slavchev Savov
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersHenderson, NV
ExchangeOTC: NIKA
Employees—
IPO date2024-03-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.